AZD1897

AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431) . This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways[1][2].

Product Specifications

CAS Number

[1204181-93-0]

UNSPSC

12352005

Target

Pim

Type

Reference compound

Related Pathways

JAK/STAT Signaling

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/azd1897.html

Purity

99.69

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCl; heat to 60°C)

Smiles

O=C(NC/1=O)SC1=C/C2=CC=CC(OC(C)C)=C2N3C[C@H](N)CCC3

Molecular Formula

C18H23N3O3S

Molecular Weight

361.46

References & Citations

[1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22 (14) :4599-604. |[2]Meja K, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol. 2014 Oct;167 (1) :69-79.